CTN Webinar: Relapse Prevention.
CTN Webinar: Relapse Prevention. – This 90-minute webinar, produced by the National Drug Abuse Treatment Clinical Trials Network (CTN) Clinical Coordinating Center for CTN members and the public, explores the issue of relapse among individuals with substance use disorders (SUD). Outcome studies, types and effects of lapse and relapse, and factors contributing to relapse are reviewed. A major emphasis of the webinar is on discussing specific clinical strategies to reduce relapse risk, with a focus on current empirical and clinical literature, including findings from quality improvement studies and clinical trials conducted in a drug treatment clinic. The target audience is CTN members and other researchers and clinicians interested in learning more about relapse prevention. Presented by Dennis Daley, PhD, LSW (Western Psychiatric Institute and Clinic, AT Node) and Dennis M. Donovan, PhD (Alcohol & Drug Abuse Institute, University of Washington, PN Node). For more resources related to this webinar, as well as other webinars in this series, visit: ctndisseminationlibrary.org
Dispute Develops Over Discount Drug Program
Filed under: drug abuse treatment outcome study
The program, known as 340B, requires most drug companies to provide hefty discounts — typically 20 to 50 percent — to hospitals and clinics that treat low-income and uninsured patients. But despite the seemingly admirable goal, the program is … “It …
Read more on New York Times
Independent Study Demonstrates Clinical Advantages Of Kiva® Over Balloon …
Filed under: drug abuse treatment outcome study
The study concluded several statistically significant outcomes in favor of Kiva over balloon kyphoplasty, the current gold standard of care and most common vertebral augmentation treatment in the United States: … KAST is being conducted to support a …
Read more on Sacramento Bee
Imprimis Announces Successful Results from its Pharmacokinetic Study for its …
Filed under: drug abuse treatment outcome study
In addition, the amount of the drug in the bloodstream after taking an oral dose of ketoprofen was studied in 40 healthy volunteers assigned to one of two cohorts (2g or 4g applications). Subjects were dosed according to a four-sequence, four-treatment …
Read more on Sacramento Bee